# ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers

> **NCT01483911** · PHASE1 · COMPLETED · sponsor: **Ablynx, a Sanofi company** · enrollment: 60 (actual)

## Conditions studied

- RSV Infection

## Interventions

- **BIOLOGICAL:** ALX-0171
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT01483911
- **Lead sponsor:** Ablynx, a Sanofi company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-05
- **Final completion:** 2012-05
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-07-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01483911

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01483911, "ALX-0171 Phase I Study, Evaluating Single Ascending Dose and Multiple Dose in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01483911. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*